Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19
Lucas C. Godoy, Ewan C. Goligher, Patrick R. Lawler, Arthur S. Slutsky, Ryan Zarychanski
Abstract
oronavirus disease 2019 (COVID-19), the disease resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exhibits a broad spectrum of manifestations and severity. 3] Macrovascular and microvascular thrombosis may contribute to organ failure, multisystem injury and death. 6,7 However, the optimal prevention and treatment of thrombosis in COVID-19 remains uncertain. We review emerging evidence regarding COVID-19 coagulopathy (Box 1) and discuss current therapeutic directions and unanswered questions.
Topics & Concepts
CoagulopathyCoronavirus disease 2019 (COVID-19)MedicineSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakCoronavirusIntensive care medicineDiseaseSeverity of illnessBetacoronavirusCoronavirus InfectionsPandemicVirologyInternal medicineInfectious disease (medical specialty)OutbreakCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Dermatological and COVID-19 studies